Anti-FcRn antibodies for treatment of auto/allo immune conditions
View Patent ↗Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.
1. An isolated antibody or a fragment thereof which binds to human FcRn, is generated against heavy chain of human FcRn or a fragment thereof, functions as a non-competitive inhibitor of IgG binding to human FcRn and does not bind beta-2-microglobulin, and wherein the antibody or the fragment thereof binds with specificity to a peptide consisting of the sequence GEEFMNFDLKQGT (SEQ ID NO:1).
2. The antibody of claim 1 , wherein the antibody is a murine antibody.
3. The antibody of claim 1 , wherein the antibody is selected from the group consisting of polyclonal and monoclonal.
4. The antibody of claim 1 , wherein the antibody is chimeric or humanized.
5. The antibody fragment of claim 1 , wherein the fragment is selected from the group consisting of Fab, F(ab)′ 2 , Fv and ScFv.
6. The antibody of claim 1 , wherein binding to FcRn is independent of the pH over a pH range of 6.0 to 8.0.
7. The antibody of claim 3 , wherein the antibody is a monoclonal antibody.
8. A method for reducing binding of IgG to FcRn in an individual comprising the steps of
providing an isolated antibody or a fragment thereof which binds to human FcRn, is generated against heavy chain of human FcRn or a fragment thereof, is a non-competitive inhibitor of IgG binding to human FcRn and does not bind beta-2-microglobulin, and wherein the antibody or the fragment thereof binds with specificity to a peptide consisting of the sequence GEEFMNFDLKQGT (SEQ ID NO:1; and
administering the antibody or the fragment thereof to an individual in an amount sufficient to inhibit the binding of IgG to FcRn in the individual.
9. The method of claim 8 , wherein the individual has an autoimmune or alloimmune disease.
10. The method of claim 9 , wherein the autoimmune disease is immune thrombocytopenia.
11. The method of claim 10 , wherein the individual is a human.
12. The method of claim 8 , wherein the antibody is administered at a dosage of 1 mg/kg to 2 g/kg.
13. The method of claim 12 , wherein the antibody is administered at a dosage of 1 mg/kg to 200 mg/kg.